Laboratorios Bagó > Referencias > CIR 521
1. Ahrendt H, et al. Efficacy, Acceptability and Tolerability of the Combined Contraceptive Ring NuvaRing, Compared With an Oral Contraceptive Containing 30 μg of Ethinyl Estradiol and 3 mg of Drospirenone. Contraception 74(6): 451-457, Sep 2006.
2. Datos en archivo , MSD.
3. Alexander NJ, et al. Why consider vaginal drug administration?. Fertil Steril. 2004
Jul;82(1):1-12
4. Novák A, et al. The Combined Contraceptive Vaginal Ring, NuvaRing: An International Study of User Acceptability. Contraception 67(3): 187-194, Mar 2003.
5. Alexander NJ. et al. Why consider vaginal drug administration? Fertil Steril. 2004 Jul;82(1):1-12.
6. Dieben TO. et al. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol. 2002 Sep;100(3):585-93.
7. Oddsson K. et al. Efficacy and safety of a contraceptive vaginal ring compared with a combined oral contraceptive: a 1-year randomized trial. Contraception. 2005 Mar;71(3):176-82.